Valneva Se Share Price (NASDAQ: VALN)

$8.86

▲

0.02

(0.23%)

Last updated on August 30, 2025 at 1:28 am IST

$₹

Check the interactive Valneva Se Stock chart to analyse performance

Valneva Se stock performance

as on August 30, 2025 at 1:28 am IST

Today's Low:$8.79
Today's High:$8.86
$8.86
0.85%
Downside
Day's Volatility :0.85%
Upside
0.0%
52 Weeks Low:$3.62
52 Weeks High:$12.25
$8.86
59.14%
Downside
52 Weeks Volatility :70.45%
Upside
27.67%

Valneva Se Stock Returns

Period	Valneva Se	Sector (Health Care)	Index (Russel 2000)
3 Months	38.06%	3.6%	0.0%
6 Months	29.77%	-7.7%	0.0%
1 Year	21.73%	-12.6%	0.0%
3 Years	-47.37%	9.5%	-4.7%

Valneva Se Key Stats

Check Valneva Se key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$8.84
Open	$8.785
Today's High	$8.86
Today's Low	$8.785
Market Capitalization	$751.7M
Today's Volume	$35.8K
52 Week High	$12.25
52 Week Low	$3.62
Revenue TTM	$196.3M
EBITDA	$-33.4M
Earnings Per Share (EPS)	$-1.07
Profit Margin	-34.15%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-38.02%

Stock Returns calculator for Valneva Se Stock including INR - Dollar returns

The Valneva Se stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Valneva Se investment value today

Current value as on today

₹1,27,155

Returns

₹27,155

(+27.15%)

Returns from Valneva Se Stock

₹21,871 (+21.87%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Valneva Se Stock

-14%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Valneva Se Stock from India on INDmoney has decreased by -14% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Valneva Se

Name
Holdings %
Name
Holdings %
Novo A/S
2.79%
General American Investors Co Inc
0.42%
Wells Fargo & Co
0.29%
Citadel Advisors Llc
0.03%
Ironwood Investment Management LLC
0.03%
Morgan Stanley - Brokerage Accounts
0.01%

Analyst Recommendation on Valneva Se Stock

Rating

Trend

Buy

84%Buy

15%Hold

0%Sell

Based on 13 Wall street analysts offering stock ratings for Valneva Se(by analysts ranked 0 to 5 stars)

Valneva Se Share Price Target

What analysts predicted

Upside of 54.35%

Target:

$13.68

Current:

$8.86

Valneva Se share price target is $13.68, a slight Upside of 54.35% compared to current price of $8.86 as per analysts' prediction.

Valneva Se Stock Insights

Price Movement
In the last 7 days, VALN stock has moved down by -24.0%
Decreasing Revenue
Revenue is down for the last 3 quarters, 52.94M → 48.33M (in $), with an average decrease of 4.4% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -9.23M → -11.58M (in $), with an average decrease of 25.5% per quarter
VALN vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 69.9% return, outperforming this stock by 49.0%
VALN vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 112.6% return, outperforming this stock by 165.3%
Price to Sales
ForVALN every $1 of sales, investors are willing to pay $3.6, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.5 for every $1 of sales.

Valneva Se Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$140.2M	↑ 11.64%
Net Income	$-1.9M	↓ 153.43%
Net Profit Margin	-1.38%	↓ 4.27%

	FY20	Y/Y Change
Revenue	$134.2M	↓ 12.58%
Net Income	$-78.3M	↑ 3592.26%
Net Profit Margin	-58.37%	↓ 56.99%

	FY21	Y/Y Change
Revenue	$393.5M	↑ 215.52%
Net Income	$-83.0M	↑ 14.03%
Net Profit Margin	-21.09%	↑ 37.28%

	FY22	Y/Y Change
Revenue	$382.4M	↑ 3.8%
Net Income	$-151.6M	↑ 95.14%
Net Profit Margin	-39.66%	↓ 18.57%

	FY23	Y/Y Change
Revenue	$167.7M	↓ 57.46%
Net Income	$-110.6M	↓ 29.21%
Net Profit Margin	-65.99%	↓ 26.33%

	FY24	Y/Y Change
Revenue	$177.4M	↑ 10.32%
Net Income	$-12.8M	↓ 87.93%
Net Profit Margin	-7.22%	↑ 58.77%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$35.6M	↓ 21.83%
Net Income	$64.0M	↓ 283.19%
Net Profit Margin	179.86%	↑ 256.61%

	Q2 FY24	Q/Q Change
Revenue	$41.0M	↑ 16.2%
Net Income	$-26.8M	↓ 142.32%
Net Profit Margin	-65.51%	↓ 245.37%

	Q3 FY24	Q/Q Change
Revenue	$50.9M	↑ 20.4%
Net Income	$-10.3M	↓ 62.96%
Net Profit Margin	-20.16%	↑ 45.35%

	Q4 FY24	Q/Q Change
Revenue	$55.4M	↑ 15.53%
Net Income	$-38.7M	↑ 300.47%
Net Profit Margin	-69.86%	↓ 49.7%

	Q1 FY25	Q/Q Change
Revenue	$53.2M	↓ 7.01%
Net Income	$-10.0M	↓ 75.04%
Net Profit Margin	-18.75%	↑ 51.11%

	Q2 FY25	Q/Q Change
Revenue	$48.3M	↓ 1.83%
Net Income	$-11.6M	↑ 25.5%
Net Profit Margin	-23.97%	↓ 5.22%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$84.7M	↑ 9.52%

	FY20	Y/Y Change
Profit	$68.1M	↓ 26.51%

	FY21	Y/Y Change
Profit	$181.1M	↑ 185.91%

	FY22	Y/Y Change
Profit	$39.0M	↓ 76.98%

	FY23	Y/Y Change
Profit	$57.6M	↑ 43.34%

	FY24	Y/Y Change
Profit	$74.3M	↑ 34.45%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$11.5M	↓ 33.1%

	Q2 FY24	Q/Q Change
Profit	$15.7M	↑ 37.75%

	Q3 FY24	Q/Q Change
Profit	$22.4M	↑ 38.06%

	Q4 FY24	Q/Q Change
Profit	$26.9M	↑ 27.61%

	Q1 FY25	Q/Q Change
Profit	$28.3M	↑ 1.87%

	Q2 FY25	Q/Q Change
Profit	$24.2M	↓ 7.55%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$6.1M	↓ 66.09%
Investing Cash Flow	$-11.9M	↑ 266.3%
Financing Cash Flow	$-8.6M	↓ 124.87%

	FY20	Y/Y Change
Operating Cash Flow	$167.5M	↑ 2391.19%
Investing Cash Flow	$-23.5M	↑ 81.0%
Financing Cash Flow	$26.4M	↓ 382.48%

	FY21	Y/Y Change
Operating Cash Flow	$86.9M	↓ 44.17%
Investing Cash Flow	$-105.3M	↑ 381.47%
Financing Cash Flow	$174.7M	↑ 610.69%

	FY22	Y/Y Change
Operating Cash Flow	$-259.6M	↓ 419.04%
Investing Cash Flow	$-30.7M	↓ 68.8%
Financing Cash Flow	$227.6M	↑ 39.23%

	FY23	Y/Y Change
Operating Cash Flow	$-221.2M	↓ 17.36%
Investing Cash Flow	$-22.5M	↓ 29.15%
Financing Cash Flow	$68.8M	↓ 70.68%

	FY24	Y/Y Change
Operating Cash Flow	$-70.3M	↓ 66.85%
Investing Cash Flow	$80.5M	↓ 473.65%
Financing Cash Flow	$32.1M	↓ 51.36%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-37.0M	↓ 50.88%
Investing Cash Flow	$94.0M	↓ 614.53%
Financing Cash Flow	$-1.8M	↓ 103.98%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-40.7M	↑ 11.26%
Investing Cash Flow	$963.1K	↓ 98.96%
Financing Cash Flow	$-9.8M	↑ 463.36%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-11.6M	↓ 72.29%
Investing Cash Flow	$-17.1M	↓ 1818.44%
Financing Cash Flow	$57.6M	↓ 667.9%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$10.0M	↓ 190.87%
Investing Cash Flow	$4.9M	↓ 130.48%
Financing Cash Flow	$-4.8M	↓ 108.85%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-8.8M	↓ 185.53%
Investing Cash Flow	$-1.0M	↓ 120.5%
Financing Cash Flow	$-6.0M	↑ 21.61%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-2.8M	↓ 65.7%
Investing Cash Flow	$-681.0K	↓ 29.14%
Financing Cash Flow	$14.9M	↓ 366.59%

Valneva Se Technicals Summary

Sell

Neutral

Buy

Valneva Se is currently in a neutral trading position according to technical analysis indicators.

Valneva Se Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Valneva Se	20.41%	29.77%	21.73%	-47.37%	-69.57%
Regeneron Pharmaceuticals, Inc.	6.48%	-15.2%	-50.31%	-3.3%	-2.01%
Beone Medicines Ltd	1.77%	24.81%	62.78%	79.11%	29.69%
Vertex Pharmaceuticals Incorporated	-14.45%	-19.13%	-17.84%	34.68%	41.87%
Alnylam Pharmaceuticals, Inc.	13.79%	83.28%	75.87%	111.28%	242.25%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Valneva Se	72.37	NA	NA	-1.35	-0.38	-0.07	NA	1.12
Regeneron Pharmaceuticals, Inc.	14.6	14.6	1.2	39.42	0.15	0.07	0.0	287.55
Beone Medicines Ltd	NA	NA	NA	2.73	-0.05	-0.01	NA	34.32
Vertex Pharmaceuticals Incorporated	27.86	27.86	0.58	18.06	0.23	0.13	NA	67.02
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	3.92	-2.58	-0.03	NA	1.91

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Valneva Se	Buy	$751.7M	-69.57%	72.37	-34.15%
Regeneron Pharmaceuticals, Inc.	Buy	$61.4B	-2.01%	14.6	31.37%
Beone Medicines Ltd	NA	$36.5B	29.69%	NA	-3.89%
Vertex Pharmaceuticals Incorporated	Buy	$100.5B	41.87%	27.86	31.86%
Alnylam Pharmaceuticals, Inc.	Buy	$59.5B	242.25%	NA	-12.96%

About Valneva Se

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. The company was founded in 1998 and is based in Saint-Herblain, France.

Organization	Valneva Se
Employees	700
CEO	Mr. Thomas Lingelbach
Industry	Healthcare

Key Management of Valneva Se

Name	Title
Mr. Thomas Lingelbach	President, CEO & Director
Mr. Peter Buhler	Chief Financial Officer
Dr. Juan-Carlos Jaramillo M.D.	Chief Medical Officer
Ms. Dipal Patel	Chief Commercial Officer
Mr. Vincent Dequenne	Chief Operating Officer
Dr. Hanneke Schuitemaker Ph.D.	Chief Scientific Officer
Mr. Joshua Drumm Ph.D.	Vice President of Investor Relations
Ms. Kendra Wergin	General Counsel & Corporate Secretary
Ms. Laetitia Bachelot-Fontaine	VP of Global Communications & European Investor Relations
Ms. Petra Pesendorfer	Chief People Officer

Important FAQs about investing in VALN Stock from India :

What is Valneva Se share price today?

Valneva Se share price today is $8.86 as on August 30, 2025 at 1:28 am IST at the close of the market. Valneva Se share today touched a day high of $8.86 and a low of $8.79.

What is the 52 week high and 52 week low for Valneva Se share?

Valneva Se share touched a 52 week high of $12.25 and a 52 week low of $3.62. Valneva Se stock price today i.e. August 30, 2025 at 1:28 am IST is closed at $8.86, lower by 27.67% versus the 52 week high.

How to invest in Valneva Se Stock (VALN) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Valneva Se on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Valneva Se Shares that will get you 0.1693 shares as per Valneva Se share price of $8.86 per share as on August 30, 2025 at 1:28 am IST.

What is the minimum amount required to buy Valneva Se Stock (VALN) from India?

Indian investors can start investing in Valneva Se (VALN) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Valneva Se stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Valneva Se share’s latest price of $8.86 as on August 30, 2025 at 1:28 am IST, you will get 1.1287 shares of Valneva Se. Learn more about fractional shares .

What are the returns that Valneva Se has given to Indian investors in the last 5 years?

Valneva Se stock has given -69.57% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?